Oak Hill Bio and Chiesi Resume Phase 2b Clinical Study for OHB-607 to Treat Bronchopulmonary Dysplasia
Oak Hill Bio and Chiesi Group have announced the enrollment of the first patient in a resumed Phase…
FDA Delays Moderna RSV Vaccine Decision
Moderna’s RSV vaccine, mRNA-1345, has experienced a delay in FDA approval, initially expected by May 12 but now…
Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships
Novavax (NASDAQ: NVAX), a leader in vaccine innovation, today reported substantial progress in its financial and operational goals…
Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
In a landmark agreement, Novavax (NASDAQ: NVAX) has partnered with French pharmaceutical giant Sanofi to escalate the fight…
CEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study
In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)…
BIOQUAL Reports Positive Q3 Growth Following Year of Steady Performance
BIOQUAL (OTC Pink: BIOQ) is a company noted for its contributions to health science research. The company’s most…
Petros Pharmaceuticals Advances STENDRA OTC Bid with Positive FDA Feedback
Petros Pharmaceuticals, Inc. has taken a significant step toward making its erectile dysfunction drug, STENDRA, available over-the-counter (OTC),…
RAPT Therapeutics Announces Promising Phase 2 Trial Results for Tivumecirnon
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced promising results from its Phase 2 clinical trial of Tivumecirnon…
Cigna Humana Merger Plans Come To Halt
The healthcare insurance landscape was on the brink of a major shift with the potential “Cigna Humana merger…
TaiMed Biologics Unveils Promising Results for Innovative Long-Acting HIV Treatment
TaiMed Biologics, a pioneering biotechnology firm, has marked a significant milestone in the fight against HIV. The company…
Immunis, Inc. Recognized as a Finalist in the Octane High Tech Awards for Best Emerging Technology Company
Immunis, Inc., a pioneering entity in the biotechnology landscape, has achieved a significant milestone by being named a…
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
Mayo Clinic, Hibiscus BioVentures (Hibiscus), and Innoforce have announced the formation of Mayflower BioVentures, a cell and gene…
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
Ocugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial
Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…